Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850 · tracked via the Priya Life Science USA tracker

Sponsor

Pfizer

Phase

Phase 3

Started

2025-12-19

Last updated

2026-09-04

Condition(s) studied

Obesity and Overweight

Investigational drug(s) / intervention(s)

MET097 →Placebo

MET097: Once-weekly MET097 administered via subcutaneous injection

Placebo: Once-weekly placebo administered via subcutaneous injection

Study summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) Exclusion Criteria: * Have any form of diabetes * Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease

Primary outcome measure(s)

Percent change from baseline in body weight — Baseline (Day 0) to Week 64

Trial sites (169)

Facility	City	Region
Headlands Research	Scottsdale	Arizona
Alliance Research Institute	Canoga Park	California
Rolling Oaks Radiology -Palms	Oxnard	California
Clinical Innovations, Inc dba CITrials	Riverside	California
Peninsula Headlands LLC	Rolling Hills	California
Collaborative Neuroscience Research, LLC	Torrance	California
CenExcel Rocky Mountain Clinical Research, LLC	Englewood	Colorado
Research Centers of America	Hollywood	Florida
Future Medical Research (Civia Health)	Longwood	Florida
Advanced Clinical Research	Miami	Florida
Oviedo Medical Research	Oviedo	Florida
CenExel FCR - ForCare Clinical Research	Tampa	Florida
DelRicht Research	Atlanta	Georgia
CenExel iResearch, LLC	Savannah	Georgia
CenExel CBH Health	Gaithersburg	Maryland
Clinical Research Professionals	Chesterfield	Missouri
Upgrade Performance Institute	Elkhorn	Nebraska
Quality Clinical Research Inc	Omaha	Nebraska
Primary clinical Research	Papillion	Nebraska
Hassman Research Institute	Marlton	New Jersey
Forum Health_Cary (Civia)	Cary	North Carolina
Eximia EquiHealth Research	Durham	North Carolina
Sahana Optometry PLLC dba Family Eye Wellness	Holly Springs	North Carolina
TMA Headlands LLC - Wilmington	Wilmington	North Carolina
TMA Headlands LLC	Wilmington	North Carolina
Summit Headlands LLC	Portland	Oregon
Tribe Clinical Research LLC.- Greenville	Greenville	South Carolina
Palmetto Internal Medicine	Mauldin	South Carolina
Tribe Clinical Research LLC. - Spartanburg	Spartanburg	South Carolina
Civia Health Goodlettsville	Goodlettsville	Tennessee
Civia Health Nashville	La Vergne	Tennessee
Civia Health Memphis	Memphis	Tennessee
Forum Austin (Civia Health)	Austin	Texas
Cedar Health Research	Dallas	Texas
GLRI El Paso Research	El Paso	Texas
Dallas Clinical Research Center (Pillar Clinical Research)	Richardson	Texas
Pantheon Clinical Research	Bountiful	Utah
MHAT Botevgrad	Botevgrad	Bulgaria
Medical Center 4Life EOOD	Burgas	Bulgaria
Multiprofile Hospital for Active Treatment Dobrich AD (MHAT Dobrich AD)	Dobrich	Bulgaria

+ 129 more sites — see the full list on the official registry below.

More Pfizer trials in the USA

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer Active, not recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. Recruiting

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant Recruiting

Other trials for the same condition

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07311850 on ClinicalTrials.gov ↗ ← All trials in the USA